VYNE Therapeutics Inc.VYNENASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank78
3Y CAGR+36.5%
5Y CAGR+8.6%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+36.5%/yr
Quarterly compound
5Y CAGR
+8.6%/yr
Recent acceleration
Percentile
P78
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 29.41% |
| Q3 2025 | -30.77% |
| Q2 2025 | 35.00% |
| Q1 2025 | 28.57% |
| Q4 2024 | 3.45% |
| Q3 2024 | -31.82% |
| Q2 2024 | -46.67% |
| Q1 2024 | 25.00% |
| Q4 2023 | 90.05% |
| Q3 2023 | 34.74% |
| Q2 2023 | -79.07% |
| Q1 2023 | 33.85% |
| Q4 2022 | 11.56% |
| Q3 2022 | -11.79% |
| Q2 2022 | -273.03% |
| Q1 2022 | 139.07% |
| Q4 2021 | 47.15% |
| Q3 2021 | -5.44% |
| Q2 2021 | 7.79% |
| Q1 2021 | 11.36% |
| Q4 2020 | 19.51% |
| Q3 2020 | 87.80% |
| Q2 2020 | -27.59% |
| Q1 2020 | -5.89% |
| Q4 2019 | -27.04% |
| Q3 2019 | -2.03% |
| Q2 2019 | 14.91% |
| Q1 2019 | -6.71% |
| Q4 2018 | -35.82% |
| Q3 2018 | -53.20% |
| Q2 2018 | 49.30% |
| Q1 2018 | -59.82% |
| Q4 2017 | -20.07% |
| Q3 2017 | -32.86% |
| Q2 2017 | -12.38% |
| Q1 2017 | -13.13% |
| Q4 2016 | -50.14% |
| Q3 2016 | 0.00% |